Novartis to offload US rights to five ophthalmic drugs to Harrow
Harrow Health, an ophthalmic therapies developer, will acquire the exclusive US commercial rights to five FDA‑approved ophthalmic products from the Novartis group of companies for up to $175 million. Under the terms of the arrangement, the Nasdaq-listed Harrow will make a one-time payment of $130 million at closing and up to an additional $45 million […]